Contributions
Abstract: PB2156
Type: Publication Only
Background
Sickle cell disease is a global public health problem. As of 2013 about 3.2 million people have sickle-cell disease with 176,000 deaths
Aims
In this present study, we investigated the effect of 8 weeks, low dose supplementation of sustained-release of nitric oxide generating L-arginine supplement (350mg) given two times daily on the full blood count, L-arginine, nitric oxide, Pantothenic acid, plasma malondaldehyde, glutathione and total antioxidant capacity of children with sickle cell disease.
Methods
This study included children with sickle cell disease (HbSS) aged 1-14 years with mean age 7.4500 ± 0.50613 years presenting to the sickle cell clinic unit of Federal Teaching Hospital Gombe, Gombe State. Subjects received sustained release oral L-arginine supplementation of 350mg twice daily for 8 weeks.
Results
L-arginine and nitric oxide levels were significantly higher among sickle cell disease children. There were no statistically significant differences between the baseline and post L-arginine supplementation in the PCV, WBC, RBC and LYM levels of subjects (p>0.05). There was a statistically significant difference between the baseline and post L-arginine supplementation in the MCV, MCH, MCHC, PLT, NEU, EOS, MON and RDW-SD levels of subjects (p<0.05). The L-arginine and nitric oxide levels was significantly higher post supplementation compared to baseline levels (p=0.002 and 0.000 respectively). The pantothenic acid level was significantly higher at baseline compared to post supplementation levels (p=0.00). The L-arginine, nitric oxide and Total Antioxidant Capacity was significantly higher post supplementation compared to baseline levels among sickle cell disease subjects with vaso-occlusive crisis (p= 0.001, 0.01 and 0.05 respectively). The pantothenic acid and malondaldehyde levels at baseline were significantly higher than the post supplementation levels among subjects with vaso-occlusive crisis (p=0.002 and 0.000 respectively). The Total Antioxidant Capacity and Glutathione levels were significantly higher post supplementation compared to baseline levels among the sickle cell subjects (p= 0.05 and 0.000 respectively). The baseline plasma malondaldehyde level was significant higher that the post supplementation levels among the sickle cell disease subjects. There is need for more effort and resources to be dedicated to research especially in supplementation studies involving a larger population aimed at establishing specific treatment for sickle cell disease. It is recommended that L-arginine supplementation be included in the management of patients with sickle cell disease particularly those with vaso-occlusive crisis. We observed a statistically significant negative correlation between the L-arginine levels and the red cell count among sickle cell disease subjects (r= -0.350, p=0.043).
Conclusion
Session topic: 25. Sickle cell disease
Keyword(s): Sickle cell patient, sickle cell disease, Sickle cell anemia, Sickle cell
Abstract: PB2156
Type: Publication Only
Background
Sickle cell disease is a global public health problem. As of 2013 about 3.2 million people have sickle-cell disease with 176,000 deaths
Aims
In this present study, we investigated the effect of 8 weeks, low dose supplementation of sustained-release of nitric oxide generating L-arginine supplement (350mg) given two times daily on the full blood count, L-arginine, nitric oxide, Pantothenic acid, plasma malondaldehyde, glutathione and total antioxidant capacity of children with sickle cell disease.
Methods
This study included children with sickle cell disease (HbSS) aged 1-14 years with mean age 7.4500 ± 0.50613 years presenting to the sickle cell clinic unit of Federal Teaching Hospital Gombe, Gombe State. Subjects received sustained release oral L-arginine supplementation of 350mg twice daily for 8 weeks.
Results
L-arginine and nitric oxide levels were significantly higher among sickle cell disease children. There were no statistically significant differences between the baseline and post L-arginine supplementation in the PCV, WBC, RBC and LYM levels of subjects (p>0.05). There was a statistically significant difference between the baseline and post L-arginine supplementation in the MCV, MCH, MCHC, PLT, NEU, EOS, MON and RDW-SD levels of subjects (p<0.05). The L-arginine and nitric oxide levels was significantly higher post supplementation compared to baseline levels (p=0.002 and 0.000 respectively). The pantothenic acid level was significantly higher at baseline compared to post supplementation levels (p=0.00). The L-arginine, nitric oxide and Total Antioxidant Capacity was significantly higher post supplementation compared to baseline levels among sickle cell disease subjects with vaso-occlusive crisis (p= 0.001, 0.01 and 0.05 respectively). The pantothenic acid and malondaldehyde levels at baseline were significantly higher than the post supplementation levels among subjects with vaso-occlusive crisis (p=0.002 and 0.000 respectively). The Total Antioxidant Capacity and Glutathione levels were significantly higher post supplementation compared to baseline levels among the sickle cell subjects (p= 0.05 and 0.000 respectively). The baseline plasma malondaldehyde level was significant higher that the post supplementation levels among the sickle cell disease subjects. There is need for more effort and resources to be dedicated to research especially in supplementation studies involving a larger population aimed at establishing specific treatment for sickle cell disease. It is recommended that L-arginine supplementation be included in the management of patients with sickle cell disease particularly those with vaso-occlusive crisis. We observed a statistically significant negative correlation between the L-arginine levels and the red cell count among sickle cell disease subjects (r= -0.350, p=0.043).
Conclusion
Session topic: 25. Sickle cell disease
Keyword(s): Sickle cell patient, sickle cell disease, Sickle cell anemia, Sickle cell